wileyonlinelibrary.com/journal/ane Acta Neurol Scand. 2018;138:78–84.
© 2018 John Wiley & Sons A/S.
Published by John Wiley & Sons Ltd
1 | INTRODUCTION
1.1 | Background
Idiopathic Parkinson’s disease (PD), the second most common neu-
rodegenerative disorder worldwide, still has a lot to be uncovered.
Rapidly aging populations, with increasing life expectancies, suggest
PD will become an even bigger health problem in the near future.
Moreover, many patients are still available to the work market at
the point of the diagnosis, hence, generating a substantial burden
on societal expenses and private economy when they leave the
work market prematurely.
The ability to perform daily activities,
in addition to work capacity, is a useful instrument for evaluating a
therapy. This important parameter has so far not been thoroughly
1.2 | Therapies
To this day, there is only symptomatic treatment for PD. Many pa-
tients develop dyskinesias and fluctuations in motor symptoms
already within 5- 10 years of traditional oral treatment. Thus, the
Accepted: 27 February 2018
Workforce participation and activities in Parkinson’s disease
patients receiving device- aided therapy
| M. Eklund
| J. Timpka
| T. Henriksen
| D. Nyholm
| P. Odin
Department of Clinical Sciences,
Neurology, Faculty of Medicine, Lund
University, Lund, Sweden
Department of Health Sciences, Mental
Health, Activity and Participation
(MAP), Lund University, Lund, Sweden
Department of Neurology, Skåne University
Hospital, Lund, Sweden
Movement Disorder Clinic, University
Hospital of Bispebjerg, Copenhagen,
Department of Neuroscience, Uppsala
University, Uppsala, Sweden
Department of Neurology, Central Hospital,
T. Sahlström, Department of Clinical
Sciences, Neurology, Faculty of Medicine,
Lund University, Lund, Sweden.
Objectives: Many countries have an aging population, and it is thus likely that
Parkinson’s disease (PD) will become an increasing health problem. It is important to
ensure this group can use their resources in the best way possible, including remain-
ing in the work market. This study aimed to investigate workforce participation and
daily activities among patients with PD receiving device- aided therapy to provide
new knowledge that may be used to inform decisions about these therapy options.
Materials and Methods: This was a retrospective, descriptive quantitative pilot study,
including 67 patients with PD from 3 centers in Sweden and Denmark. Included pa-
tients were younger than 67 years at the time of introduction of device- aided ther-
apy. Eligible patients were identified by the Swedish national Parkinson patient
registry or by the treating neurologist. Quantitative interviews were made by
Results: A majority of the patients could perform the same, or more, amount of ac-
tivities approximately 5 years after the introduction of device- aided therapy. A small
number of patients receiving deep brain stimulation (DBS) and levodopa- carbidopa
intestinal gel (LCIG) were able to increase their work capacity within 1 year of initiat-
ing device- aided therapy and a remarkably high share could still work at the end-
point of this study, approximately 15 years since the diagnosis of PD.
Conclusions: Device- aided therapy may sustain or increase daily activities and work-
force participation in patients with PD who have not yet reached retirement age.
There is need for prospective studies, both quantitative and qualitative, to confirm
activity, device-aided therapy, Parkinson’s disease, quality of life, work